Zydus Lifesciences gets USFDA nod to produce prostrate cancer drug

Zydus Lifesciences has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing.

Leave a Reply

Your email address will not be published. Required fields are marked *